Tofersen Linked to Slow but Positive ALS Outcomes Tofersen Linked to Slow but Positive ALS Outcomes

An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.Medscape Medical News
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news